Status:
COMPLETED
Patient Centered Machine Learning Model for Bleeding and Ischemic Risk
Lead Sponsor:
Abbott Medical Devices
Collaborating Sponsors:
Icahn School of Medicine at Mount Sinai
Conditions:
Coronary Artery Disease
Percutaneous Coronary Intervention
Eligibility:
All Genders
18-99 years
Brief Summary
Dual antiplatelet therapy (DAPT) is indicated in all patients undergoing coronary stent implantation to prevent ischemic recurrencies despite an increased risk of bleeding. Accordingly, clinical pract...
Detailed Description
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the standard of care for secondary prevention after percutaneous coronary intervention (PCI). DAPT has demonstrated its efficacy ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Subject must be at least 18 years of age
- Subject must provide informed consent to participate in the XIENCE study
- Subject underwent PCI with the XIENCE stent
- Exclusion criteria:
- • none
Exclusion
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
19000 Patients enrolled
Trial Details
Trial ID
NCT06089304
Start Date
May 1 2008
End Date
October 1 2023
Last Update
October 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029